Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifampin + ethambutol + pyrazinamide
- Development stage
- Unknown
- Lead developer
- Centers for Disease Control and Prevention
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
REZ is a three-drug antituberculosis treatment regimen consisting of rifampin, ethambutol, and pyrazinamide. It is specifically utilized for patients who cannot tolerate or have resistance to isoniazid, a standard component of first-line tuberculosis therapy. The regimen was evaluated by the Centers for Disease Control and Prevention (CDC) Tuberculosis Trials Consortium (TBTC) in Study 24 as a 6-month intermittent (twice or thrice weekly) course. Rifampin inhibits bacterial RNA polymerase; ethambutol interferes with cell wall synthesis by inhibiting arabinosyl transferase; and pyrazinamide's mechanism involves disruption of membrane potential and transport, particularly in acidic environments.
- Other names
- REZ regimenRifampin-Ethambutol-Pyrazinamide
02
Targets
embB (Arabinosyltransferase EmbB)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on rifampin + ethambutol + pyrazinamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifampin + ethambutol + pyrazinamide.